CA ATLANTIQUE VENDEE-CCI (CRAV.PA) Fundamental Analysis & Valuation

EPA:CRAV • FR0000185506

Current stock price

127.6 EUR
-1.4 (-1.09%)
Last:

This CRAV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRAV.PA Profitability Analysis

1.1 Basic Checks

  • CRAV had positive earnings in the past year.
  • CRAV had a negative operating cash flow in the past year.
  • CRAV had positive earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CRAV reported negative operating cash flow in multiple years.
CRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFCRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • CRAV has a Return On Assets of 0.24%. This is amonst the worse of the industry: CRAV underperforms 91.82% of its industry peers.
  • CRAV's Return On Equity of 1.94% is on the low side compared to the rest of the industry. CRAV is outperformed by 91.82% of its industry peers.
Industry RankSector Rank
ROA 0.24%
ROE 1.94%
ROIC N/A
ROA(3y)0.32%
ROA(5y)0.31%
ROE(3y)2.73%
ROE(5y)2.61%
ROIC(3y)N/A
ROIC(5y)N/A
CRAV.PA Yearly ROA, ROE, ROICCRAV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 2 3 4

1.3 Margins

  • The Profit Margin of CRAV (14.89%) is worse than 83.64% of its industry peers.
  • CRAV's Profit Margin has declined in the last couple of years.
  • The Operating Margin and Gross Margin are not available for CRAV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 14.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.77%
PM growth 5Y-7.27%
GM growth 3YN/A
GM growth 5YN/A
CRAV.PA Yearly Profit, Operating, Gross MarginsCRAV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CRAV.PA Health Analysis

2.1 Basic Checks

  • CRAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRAV remains at a similar level compared to 1 year ago.
  • CRAV has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CRAV has an improved debt to assets ratio.
CRAV.PA Yearly Shares OutstandingCRAV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
CRAV.PA Yearly Total Debt VS Total AssetsCRAV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • A Debt/Equity ratio of 0.07 indicates that CRAV is not too dependend on debt financing.
  • CRAV's Debt to Equity ratio of 0.07 is amongst the best of the industry. CRAV outperforms 88.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC5.54%
CRAV.PA Yearly LT Debt VS Equity VS FCFCRAV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRAV.PA Yearly Current Assets VS Current LiabilitesCRAV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRAV.PA Growth Analysis

3.1 Past

  • CRAV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.18%.
  • Measured over the past years, CRAV shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.30% on average per year.
  • CRAV shows a decrease in Revenue. In the last year, the revenue decreased by -0.96%.
  • Measured over the past years, CRAV shows a small growth in Revenue. The Revenue has been growing by 2.10% on average per year.
EPS 1Y (TTM)-0.18%
EPS 3Y-8.94%
EPS 5Y-5.3%
EPS Q2Q%-7.51%
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y0.89%
Revenue growth 5Y2.1%
Sales Q2Q%-7.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRAV.PA Yearly Revenue VS EstimatesCRAV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

Find the best growth stocksShow best growing peers

1

4. CRAV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.68, which indicates a very decent valuation of CRAV.
  • Based on the Price/Earnings ratio, CRAV is valued a bit more expensive than the industry average as 68.18% of the companies are valued more cheaply.
  • The average S&P500 Price/Earnings ratio is at 25.23. CRAV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.68
Fwd PE N/A
CRAV.PA Price Earnings VS Forward Price EarningsCRAV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRAV.PA Per share dataCRAV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1K 2K 3K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. CRAV.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.74%, CRAV has a reasonable but not impressive dividend return.
  • With a Dividend Yield of 2.74, CRAV pays less dividend than the industry average, which is at 4.75. 80.00% of the companies listed in the same industry pay a better dividend than CRAV!
  • Compared to an average S&P500 Dividend Yield of 1.89, CRAV pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.74%

5.2 History

  • The dividend of CRAV has a limited annual growth rate of 0.59%.
Dividend Growth(5Y)0.59%
Div Incr Years0
Div Non Decr Years0
CRAV.PA Yearly Dividends per shareCRAV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
CRAV.PA Yearly Income VS Free CF VS DividendCRAV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

More info and screens

Find the best dividend stocksShow peers with best dividend

CRAV.PA Fundamentals: All Metrics, Ratios and Statistics

CA ATLANTIQUE VENDEE-CCI

EPA:CRAV (3/20/2026, 7:00:00 PM)

127.6

-1.4 (-1.09%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)02-02
Earnings (Next)04-28
Inst Owners2.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap153.12M
Revenue(TTM)541.14M
Net Income(TTM)80.56M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.74%
Yearly DividendN/A
Dividend Growth(5Y)0.59%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 11.68
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)10.92
EY8.56%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-350.73
FCFYN/A
OCF(TTM)-318.29
OCFYN/A
SpS450.95
BVpS3455.02
TBVpS3450.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number921.36
Profitability
Industry RankSector Rank
ROA 0.24%
ROE 1.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.89%
GM N/A
FCFM N/A
ROA(3y)0.32%
ROA(5y)0.31%
ROE(3y)2.73%
ROE(5y)2.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.77%
PM growth 5Y-7.27%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.95%
Cap/Sales 7.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC5.54%
ROIC/WACCN/A
Cap/Depr(3y)179.19%
Cap/Depr(5y)167.09%
Cap/Sales(3y)6.69%
Cap/Sales(5y)6.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.18%
EPS 3Y-8.94%
EPS 5Y-5.3%
EPS Q2Q%-7.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y0.89%
Revenue growth 5Y2.1%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.49%
FCF growth 3Y-41.96%
FCF growth 5Y-14.64%
OCF growth 1Y67.7%
OCF growth 3Y-39.13%
OCF growth 5Y-12.88%

CA ATLANTIQUE VENDEE-CCI / CRAV.PA Fundamental Analysis FAQ

What is the fundamental rating for CRAV stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRAV.PA.


What is the valuation status for CRAV stock?

ChartMill assigns a valuation rating of 1 / 10 to CA ATLANTIQUE VENDEE-CCI (CRAV.PA). This can be considered as Overvalued.


What is the profitability of CRAV stock?

CA ATLANTIQUE VENDEE-CCI (CRAV.PA) has a profitability rating of 1 / 10.


What are the PE and PB ratios of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) stock?

The Price/Earnings (PE) ratio for CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 11.68 and the Price/Book (PB) ratio is 0.04.


What is the financial health of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) stock?

The financial health rating of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 2 / 10.